RLAY Q3 2022 Earnings — Relay Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RLAYRelay Therapeutics, Inc.

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$344,000-48.3% YoY

Gross Profit

-$67M-19347.7% margin

Operating Income

-$86M-24968.6% margin

Net Income

-$84M-24468.6% margin

EPS (Diluted)

$-0.79

QoQ Revenue Growth

-5.8%

Cash Flow

Operating Cash Flow

-$66M

Free Cash Flow

-$68M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$169M

Stockholders' Equity

$1000M

Cash & Equivalents

$355M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$344,000	$666,000	-48.3%
Gross Profit	-$67M	-$43M	-53.0%
Operating Income	-$86M	-$61M	-40.8%
Net Income	-$84M	-$61M	-38.4%

Revenue Segments

License

$300,000100%